$695 Million is the total value of Octagon Capital Advisors LP's 36 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | ROIVANT SCIENCES LTD | $28,811,520 | – | 3,904,000 | +100.0% | 4.14% | – | |
| New | JASPER THERAPEUTICS INC | $11,552,325 | – | 6,382,500 | +100.0% | 1.66% | – | |
| TVTX | New | TRAVERE THERAPEUTICS INC | $11,132,550 | – | 495,000 | +100.0% | 1.60% | – |
| DYN | New | DYNE THERAPEUTICS INC | $7,982,726 | – | 692,945 | +100.0% | 1.15% | – |
| GERN | New | GERON CORP | $4,943,260 | – | 2,278,000 | +100.0% | 0.71% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $4,667,930 | – | 577,000 | +100.0% | 0.67% | – |
| ANNX | New | ANNEXON INC | $4,581,500 | – | 1,190,000 | +100.0% | 0.66% | – |
| GLYC | New | GLYCOMIMETICS INC | $3,780,000 | – | 3,000,000 | +100.0% | 0.54% | – |
| RPHM | New | RENEO PHARMACEUTICALS INC | $2,511,600 | – | 420,000 | +100.0% | 0.36% | – |
| New | STRUCTURE THERAPEUTICS INCsponsored ads | $2,228,933 | – | 93,692 | +100.0% | 0.32% | – | |
| BBIO | New | BRIDGEBIO PHARMA INCcall | $1,658,000 | – | 100,000 | +100.0% | 0.24% | – |
| CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $1,524,600 | – | 396,000 | +100.0% | 0.22% | – |
| VECT | New | VECTIVBIO HLDG AG | $300,054 | – | 35,259 | +100.0% | 0.04% | – |
| PIRS | New | PIERIS PHARMACEUTICALS INC | $294,254 | – | 301,490 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.